By IDSE News Staff
Forty-one patients from 12 states who are living with HIV/AIDS or were on pre-exposure prophylaxis (PrEP) filed a personal injury lawsuit against Gilead Sciences, claiming that it failed to rectify a known defect in the drug formulation of one of its most widely prescribed medications, tenofovir disoproxil fumarate (TDF), knowing that a safer alternative, tenofovir alafenamide (TAF), existed in its own laboratory; its failure to warn patients of the damaging side effects of